CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Convalescent Plasma (anti-SARS-CoV-2 plasma)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug1633 Non-convalescent Plasma (control plasma) Wiki 0.71
drug637 Control (albumin 5%) Wiki 0.71
drug1921 Prone position Wiki 0.41

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D002032 Bulimia NIH 0.71
D001068 Feeding and Eating Disorders NIH 0.35
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0100739 Bulimia HPO 0.71

There are 2 clinical trials

Clinical Trials

1 A Phase 2, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19

This randomized blinded phase 2 trial will assess the efficacy and safety of Anti-SARS-CoV-2 convalescent plasma among adults with severe COVID-19. Adults ≥18 years of age may participate. A total of 105 eligible subjects will be randomized in a 2:1 ratio to receive either high-titer anti-SARS-CoV-2 plasma or non-convalescent fresh frozen plasma (control plasma).

NCT04359810 SARS-CoV Infection Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma) Biological: Non-convalescent Plasma (control plasma)
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: The efficacy of treatment will be determined by determining the time-to-clinical improvement, defined as the time from randomization to either an improvement of one point on a seven-category ordinal scale or alive discharge from the hospital, whichever comes first.

Measure: Time to Improvement

Time: Up to 28 days

Secondary Outcomes

Description: Compare the rates of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.

Measure: Rate of SARS-CoV-2 PCR Positivity

Time: Up to 14 days

Description: Compare the duration of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.

Measure: Duration of SARS-CoV-2 PCR Positivity

Time: Up to 14 days

Description: Compare duration of need for supplemental oxygen and/or mechanical ventilation amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.

Measure: Duration of Need for Supplemental Oxygen

Time: Up to 28 days

Description: Compare duration of hospitalization amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.

Measure: Duration of Hospitalization

Time: Up to 28 days

Description: Compare in-hospital and 28-day mortality amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.

Measure: In-hospital 28-day Mortality Rate

Time: Up to 28 days

2 A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 Cases

This is a double-blinded, randomized control trial to assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in two groups, RT PCR-positive and asymptomatic or mildly symptomatic at baseline (group B) and PCR-negative at baseline (group C). Both groups will be randomized 1:1 to receive either convalescent plasma qualitatively positive for SARS-CoV-2 antibody (anti-SARS-CoV-2 plasma) or control (albumin 5%).

NCT04390503 SARS-CoV 2 COVID-19 Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma) Biological: Control (albumin 5%)

Primary Outcomes

Description: The efficacy of treatment will be determined by rating disease severity on Day 28, or last rating evaluated, using a seven-category severity scale.

Measure: Rate of Severe Disease

Time: Up to 28 days

Secondary Outcomes

Description: To compare the rate of measurable anti-SARS-CoV-2 titers between recipients of CP (anti-SARS-CoV-2 plasma) versus control (albumin 5%).

Measure: Rate of measurable anti-SARS-CoV-2 titers

Time: Up to 90 days

Description: Compare the rates of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (albumin 5%).

Measure: Rate of SARS-CoV-2 PCR Positivity

Time: Up to 28 days

Description: Compare the duration of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (albumin 5%).

Measure: Duration of SARS-CoV-2 PCR Positivity

Time: Up to 28 days

Description: Compare the levels of SARS-CoV-2 RNA between the recipients of antiSARS-CoV-2 plasma and control (albumin 5%)

Measure: Levels of SARS-CoV-2 RNA

Time: Up to 28 days

No related HPO nodes (Using clinical trials)